Optimized DNA sequence encoding Human extracellular domain of human CD66c was fused with the C-terminal polyhistidine-tagged at the C-terminus was expressed in HEK293 cells.
Recombinant Human CD66c is a monomer protein .The reduced monomer consists of 300 amino acids and has a predicted molecular mass of approx 32kDa. In SDS-PAGE under reducing conditions, the apparent molecular mass of CD66c monomer is approximately 50 kDa due to glycosylation.
>95%, as determined by SDS-PAGE and HPLC
The activity was tested by immobilized recombinant CD66c (10ug/ml) ability to bind recombinant human CD66b in functional ELISA.
Endotoxin content was assayed using a LAL gel clot method.
Endotoxin level was found to be less than 0.1 ng/µg(1EU/µg).
Recombinant human CD66c is supplied as a 0.2 μm filtered PBS solution, pH7.2 .
Recombinant CD66c, as supplied, can be stored in working aliquots at 2° - 8° C for one month, or at -20°C to -70°C for twelve months.
Avoid repeated freeze/thaw cycles.
This product is for research purposes only.It may not be used for therapeutics or diagnostic purposes.
CEACAM6 (CD66c) and CEACAM8
(CD66b) are cell-adhesion
proteins onneutrophils that
belong to the human
(CEA)family. CEACAM6 reveals
homophilic adhesion and
other CEACAM family antigens
including CEACAM8, CEACAM1,
and CEA,whereas CEACAM8
exhibits only heterophilic
adhesion to CEACAM6
influenza a virus neuraminidase protein enhances cell survival through interaction with carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) protein
J. Biol. Chem.,
15109 - 15117.
significance of CEACAM6 expression in biliary tract carcinoma.
ASCO Meeting Abstracts,
identification of CEACAM6 as an intermediate filament-associated protein expressed in sertoli cells of rat testis
924 - 933.
protein expression analysis of alcam and CEACAM6 in breast cancer metastases reveals significantly increased alcam expression in metastases of the skin
J. Clin. Pathol.,
146 - 152.
design and activity of a murine and humanized anti-CEACAM6 single-chain variable fragment in the treatment of pancreatic cancer
1933 - 1940.